Today: 9 April 2026
Rivian stock slips again in premarket after CEO share-sale disclosure, with Tesla deliveries next
31 December 2025
1 min read

Rivian stock slips again in premarket after CEO share-sale disclosure, with Tesla deliveries next

NEW YORK, December 31, 2025, 06:05 ET — Premarket

  • Rivian shares were down about 0.9% in premarket trading after a 5.2% slide in the prior session.
  • A regulatory filing showed CEO R.J. Scaringe sold 17,450 shares under a pre-arranged trading plan.
  • Traders are watching Tesla’s delivery report and Rivian’s quarter-end production and delivery update for demand signals.

Rivian Automotive shares were down about 0.9% in premarket trading on Wednesday at $19.42, after the stock fell 5.2% in the previous session. https://www.futunn.com/en/stock/RIVN-US

The decline has kept focus on an insider-trading disclosure that surfaced as markets moved into the year’s final, lower-liquidity stretch, when smaller orders can move prices more than usual.

That matters now because Rivian’s stock has been a high-volatility trade, and investors are sensitive to signals around funding risk and demand trends across the electric-vehicle sector.

Insider sales can weigh on sentiment because some investors interpret them as a confidence signal, even when the transactions were scheduled in advance and are not tied to fresh company developments.

A Form 4 filing showed Chief Executive Officer R.J. Scaringe sold 17,450 shares on Dec. 23 at a weighted average price of $21.4253 in transactions ranging from $21.21 to $21.69, and said the sale was made under a Rule 10b5-1 plan, a pre-arranged trading program that sets trades ahead of time. https://www.sec.gov/Archives/edgar/data/1874178/000187417825000102/wk-form4_1734999771.xml

Rule 10b5-1 plans are designed to reduce concerns that executives are trading based on material nonpublic information, but the headline “insider sale” can still pressure crowded trades.

Rivian’s slide has also come as investors look for near-term reads on EV demand. Tesla is expected to report lower fourth-quarter deliveries on Friday, after the loss of U.S. tax credits and heavier competition, Reuters reported. https://www.reuters.com/business/autos-transportation/tesla-quarterly-deliveries-seen-falling-lack-tax-credits-competition-sap-demand-2025-12-30/

Broader markets have been prone to abrupt rotations in holiday-thin trade. “It’s just a healthy rebalancing of allocations,” Mark Hackett, chief market strategist at Nationwide, said in a Reuters report on Tuesday’s session. https://www.reuters.com/business/us-stock-futures-stabilize-after-tech-led-dip-halts-year-end-rally-2025-12-30/

For Rivian, investors have kept the spotlight on cash burn — how quickly the company spends cash to fund operations — and whether production efficiency and higher-margin software revenue can narrow losses.

The next company-specific checkpoint is Rivian’s quarterly production and delivery update, which the company has historically released shortly after the quarter ends, alongside timing for its results call. https://rivian.com/investors

On the chart, traders have been watching whether the shares can hold above Tuesday’s intraday low near $19.28 after opening around $20.68, levels that often become near-term support and resistance. https://stockanalysis.com/stocks/rivn/hist…

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:13 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
XPeng stock today: XPEV slides in premarket as China trade-in subsidies and new G7 REEV grab attention
Previous Story

XPeng stock today: XPEV slides in premarket as China trade-in subsidies and new G7 REEV grab attention

Robinhood stock slips in premarket after December trading snapshot; Barclays flags crypto softness
Next Story

Robinhood stock slips in premarket after December trading snapshot; Barclays flags crypto softness

Go toTop